Literature DB >> 32191798

A complementary new drug for PNH.

Robert A Brodsky1.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32191798     DOI： 10.1182/blood.2020004959

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  2 in total

1.  Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.

Authors:  Raymond S M Wong; Humphrey W H Pullon; Ismail Amine; Andrija Bogdanovic; Pascal Deschatelets; Cedric G Francois; Kalina Ignatova; Surapol Issaragrisil; Pimjai Niparuck; Tontanai Numbenjapon; Eloy Roman; Jameela Sathar; Raymond Xu; Mohammed Al-Adhami; Lisa Tan; Eric Tse; Federico V Grossi
Journal:  Ann Hematol       Date:  2022-07-22       Impact factor: 4.030

2.  Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.

Authors:  Austin G Kulasekararaj; Morag Griffin; Saskia Langemeijer; Kensuke Usuki; Alexander Kulagin; Masayo Ogawa; Ji Yu; Arshad Mujeebuddin; Jun-Ichi Nishimura; Jong Wook Lee; Régis Peffault de Latour
Journal:  Eur J Haematol       Date:  2022-06-16       Impact factor: 3.674
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.